Fig. 1.
Study design. BID twice daily, ECG electrocardiogram. aBumetanide oral liquid formulation; dose adapted by body weight. Patients < 25 kg will receive bumetanide 0.02 mg/kg BID (0.04 ml/kg oral liquid formulation BID); patients ≥ 25 kg will receive bumetanide 0.5 mg BID (1 ml oral liquid formulation BID); bPatients < 25 kg will receive placebo oral solution of 0.04 ml/kg BID; patients ≥ 25 kg will receive placebo oral solution 1 ml BID